pbyronz

[ESMO Open @ESMO_Open]

Safety analyses of the INAVO120 randomised ph III trial of inavolisib or placebo with palbociclib–fulvestrant in pts with PIK3CA-mutated, HR+, HER2-, endocrine-resistant advanced BC in @ESMO_Open. Consistent, manageable & tolerable safety profile. https://t.co/BesO0waQUh

[ESMO Open @ESMO_Open]

Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer in @ESMO_Open. No benefit of scalp cooling in terms of hair preservation or quality of life.G2 alopecia primary reason for scalp cooling discontinuation. https://t.co/uKW3G2S6gg

[ESMO Open @ESMO_Open]

Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal mts: a large-scale multicenter retrospective study (FURMO-LM) in @ESMO_Open. Potential of combination therapies in this difficult population. https://t.co/5xtMZ8OVwe

[ESMO Open @ESMO_Open]

Impact of treatment discontinuation among patients with MSI or MRD metastatic CRC treated with immune checkpoint inhibitors in @ESMO_Open. Early discontinuation of ICIs in patients without progression did not compromise PFS or OS https://t.co/JFd60aTeru

[ESMO Open @ESMO_Open]

Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell RCC: results from a global RWE study in @ESMO_Open. Large retrospective cohort, rechallenge 6 months or more after previous ICI led to improved PFS & OS. https://t.co/JtzzUEUEIw

[ESMO Open @ESMO_Open]

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies in @ESMO_Open. Most common TRAES: IRRs (n:14; 7 of G3), pyrexia, myalgia, rash. SD as best response in 39.3% of pts. https://t.co/JqZcKiaSeX

[ESMO Open @ESMO_Open]

Compartment-specific immune and tumor markers associated with clinical outcomes in pts with & without sarcomatoid/rhabdoid RCC treated with ipi & nivo in @ESMO_Open. Better outcomes in PD-L1 high. Increased neutrophils infiltration in sarc/rhabd. https://t.co/X4SOqULK3N

[ESMO Open @ESMO_Open]

Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma in @ESMO_Open. 1yr & 2yrs OS rate >70% & >50%, pure WD better PFS, potential prognostic role of CDH18 IHC. https://t.co/rKzqpGm7KO

[ESMO Open @ESMO_Open]

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia in @ESMO_Open. 969 pts, 6 studies: consistent safety profile, some differences between NA/Europe and Asia. https://t.co/Ovq4fKsgRX

[ESMO Open @ESMO_Open]

A randomized Ph3 clinical trial of weekly vs tri-weekly cisplatin-based CRT for LA cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study in @ESMO_Open.No survival differences, better tolerability and QoL for tri-weekly administration. https://t.co/P8UWWzpqOO

[ESMO Open @ESMO_Open]

TBCRC 035: randomized ph II pharmacodynamic study of standard and reduced-dose palbociclib with ET in HR+ previously treated metastatic BC in @ESMO_Open. Lower dose of palbociclib may reduce severe neutropenia without compromising molecular response. https://t.co/zxYXmaBtiH

[ESMO Open @ESMO_Open]

Ph3 trial of infigratinib vs gem/cis in advanced CCA with FGFR2 fusion/rearrangement: results & reflections on early termination of PROOF 301 in @ESMO_Open. 48/300 randomized pts in >3yrs. New frameworks needed to assess therapies in ultra-rare tumors. https://t.co/7bHLOGu3ec

[ESMO Open @ESMO_Open]

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. https://t.co/3SKc65HRwt

[ESMO Open @ESMO_Open]

PFS2 as a surrogate endpoint for OS in breast cancer randomized controlled clinical trials in @ESMO_Open. Context-dependent association, stronger association with higher PFS2 maturity and OS information fraction. https://t.co/ViDkQjXjOA

[ESMO Open @ESMO_Open]

A novel BRCAm classification system reveals differential responses to PARP inhibition and prognostic outcomes in eOC: a multicenter study in @ESMO_Open. New BRCA1m classification system identifies superior PARPi response in DBD/DBD-BRCT region. https://t.co/d8VHzmtGLJ

[ESMO Open @ESMO_Open]

ctDNA in neoadjuvant endocrine therapy for early BC in @ESMO_Open. ctDNA detection before & after neoadjuvant endocrine therapy predicts tumor burden & long-term recurrence risk. Tissue-free ctDNA assays may guide surgery & treatment decisions! https://t.co/xSuyEvKZUF

[ESMO Open @ESMO_Open]

Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for irAEs in NSCLC in @ESMO_Open. High steroid peak dose associated with reduced survival, but not cumulative dose/2nd line immunesuppression. https://t.co/36GhbzCHlc

[ESMO Open @ESMO_Open]

Global advances and future directions in lung cancer care: expert consensus and strategic priorities in @ESMO_Open. Important advances but global disparities, limited trial access, & implementation challenges still hinder progress. https://t.co/P3XbXn6e80

[ESMO Open @ESMO_Open]

A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers in @ESMO_Open. Beyond “one-size-fits-all” approach to improve precision medicine in SGC in a potentially cost-effective way. https://t.co/2kXwBX8aJ6

[ESMO Open @ESMO_Open]

A Ph IV prospective study of efficacy&safety of ribociclib+letrozole as 1L therapy in older women (≥70 years) with HR+ HER2- advanced BC: the RibOB study in @ESMO_Open. Effective therapy in elderlies, frequent dose reductions/early discontinuations. https://t.co/7WVmg4Nbj5